This is a phase Ib trial of palbociclib in combination with either taselisib or pictilisib.
The study will include a dose escalation phase (Part A), and an MTD dose expansion phase
Part A: will investigate escalating doses of palbociclib with either pictilisib or taselisib
administered orally, continuously for 21 days out of a 28 day cycle in patients with advanced
solid tumours recruited simultaneously into two parallel arms (up to 24 patients in each arm
with a maximum of 48 patients in Part A).
Once the MTD is determined the combination with the optimum safety and PK/PD profile as
determined by the SRC will be taken forward to the dose expansion phase (Part B).
Part B: The MTD dose expansion phase will be conducted using the optimal combination from
Part A in two parallel arms as follows:
B1: Patients (n=25) with PIK3CA mutant ER + HER2-ve advanced breast cancers will be treated
with a triplet combination of palbociclib and either taselisib or pictilisib along with
fulvestrant. Part B1 will require at least two of the first 15 patients to respond to
progress to recruit the full 25 patients.
B2: Patients (n=20) with PIK3CA mutant advanced solid tumours including at least 8 patients
with PIK3CA mutant ER negative and/or HER2 positive breast cancers will be treated with the
doublet combination of palbociclib and either taselisib or pictilisib. Other cancers with
relevant genetic aberrations (e.g. KRAS mutations) may be considered, depending on emerging
preclinical and clinical data on these novel antitumour agents.
In total, it is expected that a minimum of 70 and up to a maximum of 93 patients will be
enrolled into the trial, the final number will depend on the number of dose escalations
required to reach DLT. If < 48 patients are enrolled in Part A, investigators will be
permitted to enrol > 45 patients in Part B, providing the maximum number of patients remains
≤93 patients across the study.
The anticipated accrual rate during the dose escalation phase is estimated at 2 patients per
month. Accrual in the expansion phase is estimated at 4 patients per month across 2 centres.
It is expected that the trial will have a duration of recruitment of 12 to 24 months.
1. Part A (dose escalation):
Patients with histologically or cytologically confirmed malignant advanced solid
tumours refractory to standard therapy or for which no suitable effective standard
therapy exists, including, but not limited to patients with PIK3CA mutant cancers, or
those with somatic mutations or other aberrations known to result in a hyperactivated
Advanced breast cancer with the following features:
- ER+ve breast cancer that has progressed on at least one line of prior endocrine
- PIK3CA mutant breast cancer progressed on at least one line of prior endocrine
therapy or chemotherapy
- breast cancer refractory to standard treatment
Part B (dose expansion):
Patients with histologically or cytologically advanced solid tumours who have
progressed on at least one prior chemotherapy regimen for advanced cancer with a
PIK3CA mutation detected from tumour and/or circulating tumour DNA. Patients with HER2
positive breast cancer should have progressed on at least two prior HER2 directed
therapies for advanced breast cancer.
Cohort B1: ER+ve and HER2-ve post-menopausal breast cancer that has progressed on at
least one prior hormone therapy for advanced breast cancer.
Cohort B2: Advanced PIK3CA mutant solid tumours, including but not limiting to triple
negative and/or HER2 positive breast cancers and lung, head and neck cancers.
NB. PIK3CA mutation may be assessed in archival tumour samples, fresh tumour samples,
or in circulating free DNA extracted from plasma or serum. A mutation will be
considered pathogenic if described to be recurrent somatic mutation in COSMIC
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). Other cancers with
relevant genetic aberrations (e.g. KRAS mutations) may be considered, depending on
emerging preclinical and clinical data on these novel antitumour agents
2. Part A: Measurable disease as assessed by RECIST 1.1 OR evaluable disease. Part B1:
Measurable disease as assessed by RECIST 1.1 Part B2: Measurable disease as assessed
by RECIST 1.1 OR evaluable disease
3. Life expectancy of at least 12 weeks
4. World Health Organisation (WHO) performance status of 0-1 with no significant
deterioration over the previous 2 weeks
5. Haematological and biochemical indices within the ranges shown below. These
measurements must be performed within one week (Day -7 to Day 1) before the patient
goes in the trial.
Haemoglobin (Hb) ≥ 10.0 g/dL Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥
100 x 109/L Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) except for patients
with documented Gilberts' disease Alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) ≤ 2.5 x (ULN) unless raised due to tumour in which case up to 5
x ULN is permissible
If creatinine > 1.5 times ULN then:
Calculated creatinine clearance ≥ 50 mL/min (uncorrected value)
Isotope clearance measurement ≥ 50mL/min (corrected)
INR <1.5 APTT <1.5x ULN
6. Female patients with reproductive potential must have a negative urine or serum
pregnancy test within 7 days prior to start of trial. Both women and men must agree to
use a medically acceptable method of contraception throughout the treatment period and
for 3 months after discontinuation of treatment.
7. 18 years of age or over with written (signed and dated) informed consent and be
capable of co-operating with treatment and follow-up.
1. Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or
chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C)
and 4 weeks for investigational medicinal products before treatment, except for
hormonal therapy with luteinizing hormone-releasing hormone (LHRH) analogues for
medical castration in patients with castrate resistant prostate cancer, which are
permitted, and bisphosphonates or RANK ligand antagonists that are permitted for the
management of bone metastases. Palliative radiotherapy is acceptable if given for bony
metastases as long as these are not indicative of disease progression. Study drug must
be stopped 3 days before radiotherapy and restarted within 28 days, as long as bone
marrow function has returned to normal.
2. Patients with prior exposure to both a CDK4/6 inhibitor and a PI3K/ATK/mTOR inhibitor
are excluded from the study. Patients with prior exposure to either a PI3K/AKT/mTOR
pathway inhibitor OR a CDK4/6 inhibitor (but not both) are allowed entry into the
trial provided that adverse effects have recovered to grade 1 or less. Prior exposure
to fulvestrant is permitted.
3. Clinically significant abnormalities of glucose metabolism as defined by any of the
- Diagnosis of diabetes mellitus types I or II (irrespective of management).
- Glycosylated haemoglobin (HbA1C) ≥7.0% at screening
- Fasting Plasma Glucose ≥ 8.3mmol/L at screening. Fasting is defined as no caloric
intake for at least 8 hours.
4. DLCO ≤ 50% of predicted value corrected for hematocrit prior to initiation of study
5. On-going toxic manifestations of previous treatments ≥ grade 1. Exceptions to this are
alopecia or certain other toxicities, which in the opinion of the Investigator should
not exclude the patient.
6. History of malabsorption syndrome or other condition that would interfere with enteral
absorption. For example active intestine inflammation (e.g., Crohn's disease or
ulcerative colitis) requiring immunosuppressive therapy.
7. History of inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis)
8. Inability or unwillingness to swallow pills, or (for patients receiving fulvestrant)
receive IM injections.
9. Known untreated or active central nervous system (CNS) metastases (progressing or
requiring corticosteroids for symptomatic control). Patients with a history of treated
CNS metastases are eligible, provided they meet all of the following criteria:
- Evaluable or measurable disease outside the CNS is present.
- Radiographic demonstration of improvement upon the completion of CNS-directed
therapy and no evidence of interim progression between the completion of
CNS-directed therapy and the baseline disease assessment for at least 28 days.
- Not requiring dexamethasone treatment
10. Major surgery (excluding minor procedures, e.g. placement of vascular access) within 4
weeks of the first dose of study treatment
11. Ability to become pregnant (or already pregnant or lactating). However, those female
patients who have a negative serum or urine pregnancy test before enrolment and agree
to use two highly effective forms of contraception (oral, injected or implanted
hormonal contraception and condom, have a intra-uterine device and condom, diaphragm
with spermicidal gel and condom) for four weeks before entering the trial, during the
trial and for six months afterwards are considered eligible.
12. Male patients with partners of childbearing potential (unless they agree to take
measures not to father children by using one form of highly effective contraception
[condom plus spermicide] during the trial and for six months afterwards). Men with
pregnant or lactating partners should be advised to use barrier method contraception
(for example, condom plus spermicidal gel) to prevent exposure to the foetus or
13. At high medical risk because of severe or uncontrolled systemic disease, such as:
uncontrolled hypertension, symptomatic congestive heart failure ≥ class 2 (refer to
appendix 4 for grading), unstable angina pectoris, stroke or myocardial infarction
within 6 months, serious cardiac arrhythmia requiring treatment, with the exceptions
of atrial fibrillation and paroxysmal supraventricular tachycardia or conduction
abnormality that has been treated and for which the patient is no longer at risk for
serious arrhythmia (e.g., Wolff-Parkinson-White syndrome treated with surgical
14. Clinically significant history of liver disease, including cirrhosis, current alcohol
abuse, or current known active infection with hepatitis B virus, or hepatitis C virus.
Active infection is defined as requiring treatment with antiviral therapy or presence
of positive test results for Hepatitis B (Hepatitis B surface antigen [HBsAg] and/or
total Hb core antibody [anti-HBc]) or Hepatitis C (Hepatitis C virus [HCV] antibody).
Unless required by local regulations, patients are not required to have HIV, HCB, or
HCV assessments at screening if these assessments have not been previously performed.
Patients who are positive for anti-HBc are eligible only if testing is also positive
for Hepatitis B surface antibody [HbsAb] and polymerase chain reaction (PCR) is
negative for HBV DNA.
Patients who are positive for HCV serology are eligible only if testing for HCV RNA is
15. Immunocompromised status due to current known active infection with HIV or due to the
use of immunosuppressive therapies for other conditions
16. Need for current chronic corticosteroid therapy, specifically dexamethasone or ≥ 10 mg
of prednisone per day or an equivalent dose of other anti inflammatory
corticosteroids. Stable use (i.e., no change in dose within 1 month prior to Day 1 of
Cycle 1) of inhaled corticosteroids is allowed.
17. Prior bone marrow transplant or extensive radiotherapy to greater than 25% of bone
marrow within eight weeks.
18. Is a participant or plans to participate in another interventional clinical trial,
whilst taking part in this Phase I study. Participation in an observational trial
would be acceptable.
19. Current malignancies of other types, with the exception of adequately treated
cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell
carcinoma of the skin. Cancer survivors, who have undergone potentially curative
therapy for a prior malignancy, have no evidence of that disease for 3 years or more
and are deemed at negligible risk for recurrence, are eligible for the trial.
20. Any other condition which in the Investigator's opinion would not make the patient a
good candidate for the clinical trial.